[{"orgOrder":0,"company":"WellSpring","sponsor":"Newport Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"WellSpring","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"WellSpring \/ Wellspring Ophthalmics","highestDevelopmentStatusID":"4","companyTruncated":"WellSpring \/ Wellspring Ophthalmics"}]

Find Clinical Drug Pipeline Developments & Deals by WellSpring

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Wellspring Ophthalmics’ newly acquired proprietary broad formulation platform is an innovative suspension comprising aqueous, amorphous nanodispersions of cyclosporine. These formulations are designed to have higher bioavailability for better efficacy ...

                          Brand Name : Undisclosed

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          March 23, 2022

                          Lead Product(s) : Cyclosporine

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Recipient : Newport Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank